ClinicalTrials.gg
RecruitingNCT07651709Updated Jun 16, 2026

Bone Management in Pregnancy Outcomes in Epilepsy

An interventional study of Supplementation with calcium + vitamin D daily. in Epilepsy, Pregnant Woman and Bone Health, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Recruiting at 1 site in China. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.

Planned enrollment
43rd of 64
80 · median 141
Started
2026
with 8 others
No phase
21 of 101
9 open now
Primary completion
2035-01
later than 40 of 40 live
Registered
96th of 101
by date

Among the 101 studies in Epilepsy with a site in China, this one is the 43rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 with no phase, reaches primary completion later than 40 of the 40 other live ones, and was the 96th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Epilepsy with a site in China, or all of them as a file.
02

Study summary

This study is aimed to evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE.

Read the detailed description

Epilepsy, a common neurological disorder, affects approximately over 70 million individuals worldwide and 0.5-1% of women of childbearing age. Management of women with epilepsy (WWE) during their pregnancy period presents significant challenges. Optimal bone metabolism management is an essential component of obstetric care. To evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE. Based on the vitamin D levels of pregnant women with epilepsy during the early stage of pregnancy, intervention measures were taken to supplement vitamin D. The bone metabolism indicators of the offspring were tested.

03

Conditions studied

  • Epilepsy
  • Pregnant Woman
  • Bone Health

Browse trials for

Keywords

  • epilepsy
  • pregnancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of focal or generalized epilepsy as defined by the International League Against Epilepsy.
  • Women of childbearing age, aged ≥18 years, planning pregnancy or in early pregnancy (≤16 weeks gestation, confirmed by last menstrual period or ultrasound) - single pregnancy.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Pre-existing conditions affecting bone metabolism: primary hyperparathyroidism, Paget's disease, multiple myeloma, chronic kidney disease ( \<60 mL/min), cirrhosis ( B/C), or untreated hyper/hypothyroidism.
  • History of metabolic complications: hypercalcemia (serum Ca²⁺ >10.5 mg/dL), nephrolithiasis, or granulomatous diseases.
  • Recent/current use of bone-modifying drugs: bisphosphonates, (≥5 mg/day prednisone equivalent for >1 month), or loop diuretics within the past year.
  • Ultrasound shows fetal malformation.
  • Presence of other severe systemic diseases deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    calcium + vitamin D group

    Intervention for epilepsy patients

    Drug: Supplementation with calcium + vitamin D daily.

  • No intervention
    standard of care group

    Epilepsy patients receive normal follow-up without any intervention.

Interventions

  • DrugSupplementation with calcium + vitamin D daily.

    Test bone metabolism indicators at 10-14 weeks of pregnancy and intervene based on vitamin D levels. * For vitamin D levels \> 20 ng/ml: Supplementation with 725 mg of calcium + 500 IU of vitamin D daily. * For 10 ng/ml \< vitamin D levels ≤20 ng/ml: Supplementation with 725 mg of calcium + 900 IU of vitamin D daily. * For vitamin D levels ≤10 ng/ml: Supplementation with 725 mg of calcium + 1300 IU of vitamin D daily.

06

What researchers measure

Primary outcomes

  1. Bone metabolisms indicators in offspring

    25-hydroxy Vitamin D (ng/ml),procollagen type 1 N-terminal propeptide (P1NP, ng/ml),osteocalcin (OC, ng/ml)

    Time frame: Childbirth

  2. Bone metabolisms indicators in offspring

    Parathyroid hormone (PTH, ng/L)

    Time frame: Childbirth

  3. Bone metabolisms indicators in offspring

    β-crosslaps (β-CTX, pg/ml)

    Time frame: Childbirth

  4. Bone metabolisms indicators in offspring

    Body length(cm)

    Time frame: Childbirth

  5. Bone metabolisms indicators in offspring

    Weight(g)

    Time frame: Childbirth

  6. Bone metabolisms indicators in offspring

    Head circumference(cm)

    Time frame: Childbirth

Secondary outcomes

  1. Live birth rate without major congenital malformations (MCMs)

    Live Birth Definition: Delivery of a fetus showing any sign of life at ≥20 weeks of gestation (WHO criteria). Major Congenital Malformations (MCMs) definition: Structural or functional abnormalities present at birth (modified from EUROCAT criteria).

    Time frame: The outcome will be assessed at two critical time points:At Birth (Day 0-7 Post-Delivery),Within 30 Days Postnatal

  2. Maternal Bone metabolisms indicators

    25-hydroxy Vitamin D (ng/ml),procollagen type 1 N-terminal propeptide (P1NP, ng/ml),osteocalcin (OC, ng/ml)

    Time frame: 12, 24, and 36 weeks of pregnancy, the time during delivery

  3. Maternal Bone metabolisms indicators

    β-crosslaps (β-CTX, pg/ml)

    Time frame: 12, 24, and 36 weeks of pregnancy, the time during delivery

  4. Maternal Bone metabolisms indicators

    Parathyroid hormone (PTH,ng/L)

    Time frame: 12, 24, and 36 weeks of pregnancy, the time during delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jan 2035, 103 months later.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 103 months is above that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Jun 16, 2026
StartEst.
Jun 2026
Primary completionEst.
Jan 2035
CompletionEst.
Jan 2035
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07651709
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jan 2035 (estimated)
Completion
Jan 2035 (estimated)
Last update
Jun 16, 2026

Study contacts

Jiajia Fang
Contact
fangjjiaj@zju.edu.cn
15215880868

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion